Introduction {#sec1-1}
============

Breast cancer is the leading cause of mortality among women worldwide, but the exact etiology of breast cancer remains unknown. DNA methylation has attracted deep investigation in past several years and it has been seen that methylation regulation of genes related to cancer (Das and Singal, 2004).

Specifically, aberrant promoter methylation takes place in several genes in cancer development and progression (Widschwendter and Jones 2002). BRCA1 (Catteau et al., 1999; Rice et al., 2000), RASSF1A (Agathanggelou et al., 2001), DAPK1 (Dulaimi et al., 2004) are frequently methylated tumor suppressor genes in breast cancer. The process of gene silencing by methylation and its role in cancer pathogenesis is well mentioned, with methylation of tumor suppressor genes, affecting transcriptional activity of the genes, believed to be the most important drivers of carcinogenesis.

Recently, attention is paid to the phenomenon of hypermethylation of disease-related genes in peripheral blood DNA and its involvement in the pathology of cancer and other diseases (Woodson et al., 2001; Widschwendter, et al., 2008; Flanagan et al., 2009; Iwamoto, Yamamoto et al., 2011). This suggested that detection of tumor DNA in the blood may serve as an early and more accessible marker of diagnosis and prognosis of breast cancer. However, the frequency of aberrant methylation in peripheral blood has not been extensively investigated. BRCA1 status may potentially be used as a prognostic marker as several studies have shown that BRCA1 mutated breast cancer is associated with poor survival (Moller et al., 2007). BRCA1 promoter methylation was observed to be significantly associated with breast cancer-specific mortality (Xu et al., 2009, Hsu et al., 2013). DNA methylation markers have been used as an alternative approach to molecular profiling of breast cancer. RASSF1A promoter methylation provides important prognostic information in early stage breast cancer patients (Widschwendter et al., 2004; Jezkova et al., 2016). Promoter methylation of DAPK1 gene was also observed to be associated with DCIS, LCIS and all grades and stages of breast cancer patients (Dulaimi et al., 2004). All of these results suggest that DNA methylation correlates with clinical findings in breast cancer and may help in the prediction of therapeutic strategy for breast cancer. Moreover, these results demonstrate that MNCs DNA may be a potential biomarker for analysis of promoter methylation status.

In current study, we investigated the promoter methylation status of BRCA1, DAPK1 and RASSF1A genes in relation to clinicopathological features and breast cancer survival in breast cancer patients.

Materials and Methods {#sec1-2}
=====================

Study Population {#sec2-1}
----------------

The current study was performed on 60 histopathologically confirmed newly diagnosed, untreated cases of North Indian breast cancer patients and 60 age-matched female healthy volunteers. Samples were collected from Department of Surgery, Lok Nayak Jaiprakash Hospital, New Delhi during January 2012 to December 2013. 5ml of peripheral blood sample was collected from each patient as well as healthy volunteer and stored at -80°C.

The study was ethically approved by Institutional Ethics Committee, Maulana Azad Medical College, New Delhi. Written informed consent was taken from each study subjects. Demographic data of patients and controls are shown in [Table 1](#T1){ref-type="table"}.

###### 

Demographic Features of Breast Cancer Patients and Healthy Controls

  Parameters           Cases (%)      Healthy Controls (%)
  -------------------- -------------- ----------------------
  Patients             60 (100%)      60 (100%)
  Age at diagnosis                    
   Age ≤ 45            26 (43.3)      25 (41.7)
   Age \> 45           34 (56.7)      35 (58.3)
  Mean±SD              49.2 ± 12.47   48.69±12.25
  Menopause                           
   Pre                 21 (35)        
   Post                39 (65)        
  TNM Stages                          
   I                   3 (5)          
   II                  29 (48.3)      
   III                 25 (41.7)      
   IV                  3 (5)          
  Tumor Grading                       
   I                   4 (6.6)        
   II                  33 (55)        
   III                 23 (38.4)      
  Lymph Node Status                   
   Positive            29 (48.4)      
   Neative             31 (51.6)      
  Chemotherapy                        
   Adjuvant            14 (23.3)      
   Neo-Adjuvant        46 (76.7)      
  ER Status                           
   Positive            11 (18.3)      
   Neative             49 (81.7)      
  PR Status                           
   Positive            9 (15)         
   Neative             51 (85)        
  HER2/neu Status                     
   Positive            23 (38.4)      
   Neative             37 (61.6)      
  Distant Metastasis                  
   Positive            3 (5)          
   Neative             57 (95)        

Patient data collection and Follow-up {#sec2-2}
-------------------------------------

Patient follow-up was done through the hospital records and confirmed by direct patient contact. Tumor characteristics and treatment information was obtained from the patient at the time of diagnosis and/or during the regular visit and verified with hospital record. The questionnaires were administrated to evaluate the demographic features and breast cancer-related features of patients. Patients with a history of any other malignancy or metastasized cancer from any other sites were excluded. The total follow-up period was 45 months and mean follow-up time was 30.98.

DNA extraction and bisulfite modification {#sec2-3}
-----------------------------------------

DNA extraction was performed on peripheral blood mononuclear Cells (PBMNCs) using Blood DNA extraction kit (Geneaid) by following manufacturer's instructions. DNA concentrations were measured and 1μg of DNA was used for bisulfite modification. DNA bisulfite modification was performed using Bisulflash DNA modification kit (Epigenetek) according to the manufacturer's instructions. Bisulfite treated DNA was immediately stored at -20°C.

Methylation Specific- Polymerase Chain Reaction (MS-PCR) Analysis {#sec2-4}
-----------------------------------------------------------------

After bisulfite conversion, Qualitative methylation status of different genes were analyzed by Methylation-Specific Polymerase Chain Reaction (MS-PCR). Primers for MS-PCR were as shown in previous studies (Estellers et al., 1999; Baldwinet al., 2000; Burbee et al., 2001) and also shown in [Table 2](#T2){ref-type="table"}. PCRs were run in a volume of 25 μl, containing 2ul bisulfite-modified DNA, 12 μl of 2x Hot Start PCR Mastermix (Fermentas), 0.25μl sense primer (25 pM), 0.25 μl antisense primer (25 pM), and 12.5μl H2O. The PCR profile was 95°C for 10 minutes, 40 cycles at 95°C for 45 seconds, primer annealing at 56°C to 60°C for 45 seconds, 72°C for 45 seconds, and a final extension step at 72°C 10 minutes. The amplified PCR products were further electrophoresed on 2% agarose gels and evaluated under ultraviolet light ([Figure 1](#F1){ref-type="fig"}).

###### 

Primer Sequence for Methylation- Specific Polymerase Chain Reaction used for BRCA1, DAPK1 and RASSF1Agenes

  Gene      Primer Name    Sense Primer                  Antisense Primer            Annealing Temp (°C)   Size (bp)
  --------- -------------- ----------------------------- --------------------------- --------------------- -----------
  BRCA1     Unmethylated   GGTTAATTTAGAGTTTTGAGAGATG     TCAACAAACTCACACCACACAATCA   56                    182 bp
            Methylated     GGTTAATTTAGAGTTTCGAGAGACG     TCAACGAACTCACGCCGCGCAATCG   56                    182 bp
  DAPK1     Unmethylated   GGAGGATAGTTGGATTGAGTTAATGTT   CAAATCCCTCCCAAACACCAA       60                    105 bp
            Methylated     GGATAGTCGGATCGAGTTAACGTC      CCCTCCCAAACGCCGA            60                    97 bp
  RASSF1A   Unmethylated   GGAGGATAGTTGGATTGAGTTAATGTT   GGTTTTTGTGAGTGTGTTTAG       60                    169 bp
            Methylated     GCTAACAAACGCGAACCG            CCCTCCCAAACGCCGA            60                    169 bp

![Representative Results of MS-PCR Analysis for (A) BRCA1, (B) DAPK1 and (C) RASSF1A in Breast Cancer Patients. Lanes M and U correspond to methylated and unmethylated samples respectively and Last Lane to a 100bp ladder as molecular weight marker.](APJCP-19-443-g001){#F1}

Statistical Analysis {#sec2-5}
--------------------

SPSS 16 and GraphPad Statistical software were used for statistical analysis of the study. Methylation frequencies between the patients and healthy volunteers were analyzed using the Chi-square test and values less than 5 were analyzed by Fisher exact test. The Cox proportional hazard regression (Hosmer, 1999) was used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for the association between gene promoter methylation status and breast cancer-specific mortality. Kaplan-Meier survival analysis was performed for overall survival of breast cancer patients. The p-value less than 0.05 was considered to be statistically significant.

Results {#sec1-3}
=======

Patient Characteristics {#sec2-6}
-----------------------

Among the cases, 26(43.3%) were age ≤ 45 age group and 34(56.7%) \>45 years group. Menopausal status shows that 21(35%) patients were in premenopausal status and 39(65%) patients were in postmenopausal status. TNM staging reveals that 32(53.3%) patients were in early stages (I and II) and 28(46.7%) patients were in advanced stages (III and IV). Histological grading of the patients shows that 4(6.6), 33(55%) and 23(38.4%) were in well differentiated, moderately differentiated and poorly differentiated, respectively. Lymph node status shows that 29(48.4%) cases were positive for lymph node metastasis. Hormone receptor status shows that 11(18.3%) patients were positive for Estrogen receptor (ER), 9(15%) patients were positive for Progesterone receptor (PR) and 23(38.4%) were HER2/neu positive. Of the total breast cancer cases, 3(5%) patients having distant metastasis.

Promoter hypermethylation and clinicopathological features of breast cancer patients {#sec2-7}
------------------------------------------------------------------------------------

Of the three tumor suppressor genes tested, All three genes (BRCA1, DAPK1 and RASSF1A) were found significantly hypermethylated (P \<0.001) in cases than the healthy controls. Their methylation levels were 31/60(51.66%) (P \<0.001), 33/60(55%) (P \<0.001), 28/60(46.6%) (P \<0.001) respectively ([Table 3](#T3){ref-type="table"}).

###### 

Association between Promoter Methylation of Tumor Suppressor Genes and Clinico- Pathological Features

                         BRCA1 Positive n(%)   p-value   DAPK1 Positive n(%)   p-value   RASSF1A Positive   p-value
  ---------------------- --------------------- --------- --------------------- --------- ------------------ ----------
  Cases (60)             31 (51.66)            \<0.001   33 (55)               \<0.001   28 (46.6)          \< 0.001
  Controls (60)          0 (0)                           0 (0)                           00 (0)             
  Age at Diagnosis                                                                                          
   Age ≤ 45 (26)         11 (42.3)             0.3       15 (57.7)             0.92      12 (46.2)          0.8
   Age \> 45 (34)        20 (58.80)                      18 (53)                         16 (47.1)          
  Menopause Stages                                                                                          
   Pre (21)              8 (38.1)              0.2       12 (57)               0.9       8 (38.1)           0.4
   Post (39)             23 (59)                         21 (53.8)                       20 (51.2)          
  TNM Stages                                                                                                
   Early (I&II) (32)     11 (34.3)             0.009     12 (37.5)             0.008     10 (31.3)          0.02
   Advanced              20 (71.4)                       21 (75)                         18 (64.3)          
  (III&IV) (28)                                                                                             
  Histological Grading                                                                                      
   I (4)                 1 (25)                0.2       1 (25)                0.38      1 (25)             0.24
   II (33)               15 (45.4)                       20 (60.6)                       13 (39.4)          
   III (23)              15 (65.2)                       12 (52.2)                       14 (60.9)          
  Lymph Nodes                                                                                               
   Positive (31)         19 (61.3)             0.19      20 (60.6)             0.3       16 (55.2)          0.5
   Negative (29)         12 (41.3)                       13 (44.8)                       12 (44.4)          
  Chemotherapy                                                                                              
   Adjuvant (14)         4 (28.6)              0.06      8 (57.1)              0.9       5 (37.8)           0.5
   Neoadjuvant (46)      27 (58.7)                       25 (54.3)                       23 (50)            
  ER Status                                                                                                 
   Positive (11)         6 (54.6)              0.9       6 (54.5)              0.76      6 (54.6)           0.8
   Negative (49)         25 (51.0)                       27 (55.1)                       23 (46.9)          
  PR Status                                                                                                 
   Positive (09)         5 (55.5)              1         5 (55.5)              0.63      5 (55.5)           0.5
   Negative (51)         26 (51)                         28 (54.9)                       24 (47.1)          
  HER2/neu                                                                                                  
   Positive (23)         12 (52.2)             0.8       14 (60.8)             0.64      11 (47.8)          0.9
   Negative (37)         19 (51.4)                       19 (51.3)                       17 (45.9)          
  Distant Metastasis                                                                                        
   Positive (03)         3 (100)               0.2       3 (100)               0.2       3 (100)            0.09
   Negative (57)         28 (49.2)                       30 (52.6)                       25 (43.9)          

We found a significant difference between tumor suppressor gene, BRCA1 (P= 0.009), DAPK1 (P= 0.008) and RASSF1A (P= 0.02)) hypermethylation with early and advanced stages of breast cancer patients ([Table 3](#T3){ref-type="table"}). No significant association was found between tumor suppressor genes (BRCA1, DAPK1 and RASSF1A) and Age at diagnosis, Menopausal status, histological grading, Lymph node status, Chemotherapy, Estrogen receptor (ER), Progesterone receptor (PR), HER2/neu and Distant metastasis.

Promoter Hypermethylation and survival analysis of breast cancer patients {#sec2-8}
-------------------------------------------------------------------------

Among total 60 cases of breast cancer, 25 patients died during the follow-up period. We found that all 25 cases died due to the advancement of the disease. [Table 4](#T4){ref-type="table"} shows the association of methylation status of BRCA1, DAPK1 and RASSF1A with breast cancer-specific mortality in Indian population. At the end of follow-up, Compared to the cases with unmethylated promoter of BRCA1, cases with methylated promoter having highest risk (HR: 3.25(1.448- 7.317)) of death due to breast cancer. In cases of promoter methylation of DAPK1, we found comparatively low but significant risk (HR: 2.32(1.05-5.11)) of breast cancer-specific mortality than BRCA1 promoter methylation. In comparison of BRCA1 and DAPK1 promoter methylation with survival, RASSF1A promoter methylation having lowest risk ((HR: 1.54(0.697-3.413)) of breast cancer-specific mortality.

###### 

Hazard Ratios (HRs) and 95% Confidence Intervals (CIs) for the Associations of Gene Promoter Methylation Status and Mortality among Indian Breast Cancer Patients

  Genes           No of Cases   No of Deaths   Hazard ratio (95%CI)
  --------------- ------------- -------------- ----------------------
  BRCA1                                        
   Unmethylated   29            7              1.00 (Ref)
   Methylated     31            18             3.25 (1.448- 7.317)
  DAPK1                                        
   Unmethylated   27            7              1.00 (Ref)
   Methylated     33            18             2.32 (1.05-5.11)
  RASSF1                                       
   Unmethylated   33            11             1.00 (Ref)
   Methylated     27            14             1.54 (0.697-3.413)

Discussion {#sec1-4}
==========

To effectively reduce the disease burden of breast cancer, it is important to identify etiologic factors of the disease as well as factors that predict survival. We studied promoter methylation of three tumor suppressor genes previously found to be associated with breast cancer-specific mortality (Cho et al., 2012).

In present study, we found a significant difference between promoter methylation of cases than controls for all three genes. Frequencies for the methylation of these three genes (BRCA1, DAPK1 and RASSF1A) were 51.66%, 55%, 46.6% respectively. Similarly, significant results were also seen in the previous studies analyzed these three genes in different populations (Bagadi et al., 2008; Ahmed et al., 2010; Cho et al., 2012; Spitzwieseret al., 2015).

A similar study was performed on the similar population by Sharma et al., (2009) found comparatively higher frequency for RASSF1A, but lower frequency for BRCA1 promoter methylation. Another study by Dulaimi et al., (2004) found almost similar frequency for DAPK1 gene in serum of breast cancer patients. This discrepancy in results was found may be due to various reasons like sample size, race, treatment status, dietary intake, family history etc. While analyzing the number of methylated genes and survival of the patients in a dose-dependent manner, we found significant decrease in overall survival with increase in number of promoter methylated genes ([Table 5](#T5){ref-type="table"}).

###### 

Number of Methylated Genes in Relation to Breast Cancer- Specific Mortality among Indian Breast Cancer Patients

  No. of genes methylated   No. of Cases   No. of Deaths   HR (95% CI)
  ------------------------- -------------- --------------- -------------------
  0                         9              2               1.00 (ref.)
  1                         21             4               0.81 (0.13-4.73)
  2                         20             12              2.50 (0.82-7.66)
  3                         10             7               4.12 (1.09-15.57)

Additionally, we found significant correlation between promoter methylation of all three genes and early and advanced stages of breast cancer patients, which demonstrate an increase in promoter methylation level with the advancement of disease. Several previous studies are in support of our findings (Singh et al., 2011; Tserga et al., 2012). Apart from TNM stages, we are not able to find any correlation between promoter methylation of these tumor suppressor genes and other clinico-pathological features of breast cancer patients.

Very limited studies were done to investigate the prognostic role of promoter methylation of these tumor suppressor genes in Indian breast cancer patients. In our study, we have seen a strong association between BRCA1 and DAPK1 promoter methylation with poor prognosis of breast cancer patients. BRCA1 and DAPK1 shown to be significantly associated with poor overall survival ([Figure 2a](#F2){ref-type="fig"} and [2b](#F2){ref-type="fig"} respectively). For RASSF1A promoter methylation, we have seen a weak association with overall survival ([Fig 2c](#F2){ref-type="fig"}). Furthermore, we have analyzed the combined effect of BRCA1 and DAPK1 methylation in survival of breast cancer patients; we found a significant decrease in breast cancer survival ([Figure 2d](#F2){ref-type="fig"}). A previous study Xu et al., (2009) also found similar association between BRCA1 promoter methylation in breast cancer patients with poor survival. Another study by Cho et al.,(2012) (found similarly weak association between RASSF1A promoter methylation and breast cancer survival.

![Kaplan -- Meier Survival Plot for Breast Cancer Patients by (a) BRCA1, (b) DAPK1, (c) RASSF1A and (d) BRCA1 + DAPK1 Promoter Methylation Status in Peripheral Blood Samples](APJCP-19-443-g002){#F2}

Few studies of BRCA1 promoter methylation in normal breast tissues have identified it in 8.3--22% of these tissues (Bean et al., 2007). However, these studies did not confirm the absence of tumor cells and benign proliferative lesions in the analyzed tissues (Bean et al., 2007; Vasilatos et al., 2009). Pu et al., (2003) observed that promoter methylation of RASSF1A was found to be more commonly in healthy female predicted to have a high risk of breast cancer.

In conclusion, we found a significant association between BRCA1, DAPK1 and RASSF1A gene promoter methylation with North Indian breast cancer patients compared to healthy controls. Promoter methylation of these three tumor suppressor genes individually and in combined significantly multiply the risk of breast cancer progression. Moreover, we also observed that promoter methylation of these genes associated with high TNM stages and Poor survival of breast cancer patients. Our results indicate that promoter methylation of BRCA1, DAPK1 and RASSF1A genes in PBMNC DNA may be associated with breast cancer progression and poorer overall survival. A large pooled study on Indian breast cancer cases is required to confirm our finding.
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